Wednesday 2 April 2014

PodMed: A Medical News Roundup from Johns Hopkins (with audio)

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 21, 2014

By Rick Lange, MD, and Elizabeth Tracey , Johns Hopkins Medicine

PodMed is a weekly podcast from Johns Hopkins Medicine. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, professor of medicine at Johns Hopkins and vice chairman of medicine at the University of Texas Health Science Center at San Antonio, look at the top medical stories of the week.

This week's topics include adverse outcomes relative to a common infection during pregnancy, antiviral drug impact, statins and MS, and genetic profiles and fatty food consumption.

Program notes:

0:32 H. influenzae and adverse pregnancy outcomes

1:30 Much more likely to be infected if pregnant

2:35 Diagnosis only when looked for

3:10 Impact of antiviral medications in flu

4:12 Compared outcomes of no treatment or antiviral

5:16 Statins and MS

6:10 Anti-inflammatory effects

7:10 Genetic profile and diet impact

8:07 Clear interaction with genetic risk and fried food consumption

9:07 Medical advice needs to be tailored

10:21 End

Rick Lange, MD, and Elizabeth Tracey

open bio MOST READ IN Infectious Disease

Coming This Week: AAD, SGO, and ACC

Sorry, I could not read the content fromt this page.

View the original article here

Morning Break: Tweeting Surgery, Bionic Limbs

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 21, 2014

Cincinnati Children's Hospital Medical Center will live Tweet from the OR as surgeons perform gastric bypass surgery on a 12-year old Texas girl who has had uncontrollable hunger following removal of a brain tumor almost 3 years ago. The girl, Alexis Shapiro, gained a national attention following a story in People.

Physician assistants are in hot demand by hospitals, according to staffing firm.

An oncology patient didn't have 8 months to wait for her daughter's wedding, so the hospital staff brought the wedding to the ICU, as reported in the New York Times.

Also in the Times yesterday, the Well blog tackles the issue of whether today's advances in medicine are generating enough of a benefit to make a difference in patients' outcomes.

A woman whose left leg was partially amputated following the Boston Marathon bombing showed off a new bionic limb by dancing a rumba at TED2014.

American Medical Association President Ardis Hoven, MD, went on C-SPAN this week to talk about how the Affordable Care Act is impacting doctors.

Republicans' Obamacare replacement bill may never see the light of day.

Florbetaben (Neuraceq) became the third PET tracer for beta-amyloid plaques to win FDA approval, following florbetapir (AmyVid) and flutemetamol (Vizamyl).

A new poll shows people want elected officials to try to make the ACA work rather than fail.

A former health official in the Clinton administration wrote in the Huffington Post that we shouldn't be quick to judge medical homes.

The Federal Trade Commission opened a two-day workshop on competition in healthcare Thursday.

Lobbyists want the FDA to hurry up on approving new sunscreen ingredients that could prevent skin cancer.

Health Affairs published a policy brief on the ICD-10 conversion. Check it out here.

Medical marijuana is coming to Alabama.

Meanwhile, debate in Connecticut heats up over a physician-assisted suicide bill. (Subscription required)

The EU's Committee for Medicinal Products for Human Use had a busy week, recommending nine new drugs for approval.

Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us:  MPT_editorial@everydayhealthinc.com.

MOST READ IN Public Health & PolicyTOP CME IN Public Health & Policy

More of the Bugs Kids Get Are Resistant

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 20, 2014

The rate of antibiotic-resistant Gram-negative bacterial infections in children is increasing in inpatient and outpatient settings, a study reports.

The prevalence of third-generation cephalosporin-resistant (G3CR) bacteria increased from 1.39% in 1999-2001 to 3% in 2010-2011, wrote Latania K. Logan, MD, of Rush University Medical Center in Chicago, and her co-authors online in the Journal of the Pediatric Infectious Disease Society.

The prevalence of extended-spectrum B-lactamase-producing (ESBL) bacteria increased from 0.28% to 0.92% in the same time frame, the authors said.

"Blood and respiratory cultures showed a higher proportion of G3CR and ESBL, rising in prevalence across patient settings, U.S. regions, and pediatric age groups represented in the data," the authors said. "Presentation in the ambulatory settings is common."

Respiratory G3CR and ESBL prevalence increased from 7.01% and 2.2% in 1999-2001 to 16.2% and 6.3% in 2010-2011 (P<0.01), respectively, they said.

The researchers used regional and national data from The Surveillance Network Database-USA, a network that includes close to 300 clinical laboratories. The analysis included all isolates of Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis from pediatric patients between the ages of 1 and 17. All specimens were collected in outpatient and inpatient settings, including the intensive care unit, between January 1999 and December 31, 2011.

Out of 368,398 pediatric isolates analyzed, 1.97% (7,255) were identified as G3CR and 0.47% (1,734) were identified as ESBL.

The majority of isolates were E. coli (67.8% for G3CR and 65.2% for ESBL).

"Increasing resistance in Enterobacteriaceae is an emerging public health threat, underscored by recent well-publicized outbreaks and national reports," the authors said.

Resistance to third-generation cephalosporins, they said, "is particularly worrisome when caused by ESBLs, as the spread of these enzymes is plasmid-mediated and can be transferred to other Gram-negative species."

The findings in this paper are consistent with previous reports of the same data in adults, which also report an upward trend, the authors said. The prevalence rate for adults was higher, ranging from 5% to 13% over the same time period used to assess the data in children.

ESBLs have been more of a problem in adult populations, possibly due to adults' greater exposure to hospitalization and indwelling devices, among other factors related to greater healthcare intervention. The clinical risk factors for children may be similar, the authors said; however, the data are limited.

"Additional studies in children to assess risk factors for acquisition, prevalence in ambulatory and long-term healthcare facilities, and the molecular epidemiology of ESBL-producing bacteria are warranted," the authors said.

The study had several limitations. Because the data came from laboratory surveillance, the researchers couldn't account for clinical characteristics or distinguish between confirmed infection and colonization.

Patient location entered in laboratory information systems may not, in fact, correspond to the clinical setting where the patient received care. And though all laboratories applied CLSI methods, "susceptibility testing was not centralized," the authors said.

Interpretive susceptibility breakpoints for cephalosporins were lowered in January 2010, which might have increased cephalosporin resistance for isolates after that date. And the analyzed data does not include Klebsiella oxytoca, which often occurs alongside Klebsiella pneumoniae.

The authors disclosed no relevant relationships with industry.

MOST READ IN Infectious Disease

Tuesday 1 April 2014

This Week in Medical News: A Link Between HIV and MS?

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking.

View the original article here

Severe Asthma, Rethinking Epi: The FOAMed Report

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 22, 2014

Here are seven must-reads curated from the globally crowd-sourced emergency medicine online education community called Free Open Access Meducation (FOAMed):

1. How to treat severe asthmatics with a focus on post-intubation/ventilator care.

2. What is "standard of care" and how does it impede the continuous march of science? Key quote: "Standard of care adopts a position of unsupported truth-value without the reason necessary for its nuanced interpretation."

3. Six takeaways about how to treat septic shock aggressively by the lead author of the NEJM ProCESS protocols study. (And here's our take with CME and video interviews.)

4. Why it's time to reconsider epinephrine in out-of-hospital-cardiac-arrest.

5. Check the ECG systematically, or risk missing something, says Amal Mattu, MD in his video on short QTc.

6. Avoid these azithromycin combos for influenza until further notice now that Ryan Radecki, MD has smacked the study down as "tragic science."

7. From damage control resuscitation to cricothyrotomy best practices, the Social Media in Critical Care (smaccGold) Top 10 list.

Thanks to Michelle Lin, MD, Salim Rezaie, MD, and guest editor Anand Swaminathan, MD.

Looking for more? Here's last week's Game-Changers edition.

What's FOAMed? Read a FOAMed primer assembled by the people who coined the term. Follow the action in real time with #FOAMed, or check out a handy calendar of EM conferences.

MOST READ IN Emergency Medicine

Morning Break: Weed for MS, Pain and Suffering $$$

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 25, 2014

A new American Academy of Neurology guideline on alternative medicine approaches to multiple sclerosis says marijuana can help with some symptoms, but is less favorable to other treatments such as bee sting therapies and the Cari Loder regimen.

The Commonwealth Fund found nearly 32 million people under age 65 were underinsured in the U.S. in 2012.

More than 1,300 doctors "received both research money and speaking or consulting fees from the same drug maker in 2012," according to ProPublica.

Petitioners want to increase the $250,000 limit on medical malpractice damages for pain and suffering in California.

Don't judge the ACA by one year's numbers, the president of the Kaiser Family Foundation wrote in a blog.

A study published Monday in the American Journal of Managed Care found patient-centered medical homes to be working in Pennsylvania.

An obsession with preventing illness is driving the "overmedicalization of our lives," writes Hilda Bastian on the SciAm blogs.

Vladimir Putin took time out from annexing the Crimea to restart a Stalin-era program aimed at boosting physical fitness in Russia. We are not making this up.

Poison control centers are confirming the dangers of e-cigarette liquids -- in Pittsburgh, for example, the number of reported incidents rose 50% from 2012 to 2013, although the absolute total remained low compared with household chemicals and prescription drugs.

Big Pharma must be more transparent when it comes to sharing data from negative trials, according to Kevin Campbell, MD.

An Ebola virus outbreak in the west African nation of Guinea has public health authorities worried about further spread of the deadly infection.

Let's make fun of public health ideas circa 1875.

Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us:  MPT_editorial@everydayhealthinc.com.

Best Bowel Prep, 100% Cancer Prevention: The Gastro and Endo News Report

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking.

View the original article here

Monday 31 March 2014

Rectal Massage for Hiccups: That&apos;s Improbable!

Sorry, I could not read the content fromt this page.

View the original article here

Shingles Vaccine OK in Mild Lupus

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 24, 2014

NEW YORK -- Vaccination against shingles may be safe for patients with mild, stable systemic lupus erythematosus, a researcher said here.

In a pilot study that included 10 lupus patients and 10 healthy controls all older than 50, there were no disease flares and safety was identical in the two groups, with three participants in each experiencing mild, transient erythema and tenderness at the injection site, according to Eliza F. Chakravarty, MD, of the Oklahoma Medical Research Foundation in Oklahoma City.

There also were no cases of vesicular or bullous lesions "or anything else that would be concerning," she said during an advanced rheumatology seminar at New York University Langone Medical Center.

"Patients with lupus have a dramatically increased risk of shingles even in their 20s and 30s, so that a 30-year-old woman with the disease has a risk of zoster that's about equivalent to a 60- or 65-year-old person with a healthy immune system," she said.

Reactivation of the varicella zoster virus occurs with senescence of cell-mediated immunity, as plasmacytoid dendritic cells produce large amounts of interferon-alpha through toll-like receptor-9 dependent and independent pathways that are also involved in the pathogenesis of lupus.

The zoster vaccine Zostavax has been available since 2006, but there are no data on either immunogenicity or safety for patients with autoimmune diseases.

Potential concerns have been whether the vaccine would result in exacerbations of lupus or more-difficult-to-manage disease, and if the vaccine itself could result in disease in these immunocompromised patients.

In addition, it's not always feasible in lupus for patients to have a drug holiday for immunizations because of the likelihood of flare.

The CDC has said that the vaccine is "probably okay" for immunosuppressed patients taking prednisone in doses below 20 mg per day, methotrexate in doses no higher than 0.4 mg/kg per week, and azathioprine in doses no higher than 3 mg/kg per day.

However, the recommendations didn't address other medications that are important in lupus, such as mycophenolate mofetil or cyclophosphamide. "So we're left in the dark," Chakravarty said.

To examine the possibility that the vaccine could be used safely in lupus patients and would generate an adequate cell-mediated immunogenic response, she and her colleagues conducted a small, open-label trial that included patients older than 50 who had IgG evidence of previous exposure and were taking medications considered acceptable in the CDC recommendations.

The participants were all women. Four of the patients and two controls had a history of shingles.

The primary safety endpoint was the appearance of any herpetiform or bullous lesions at the site of the injection.

"If we had seen any evidence of this we could have immediately instituted antiviral therapy," she said.

Only minor changes were seen on disease activity scores, primarily relating to fluctuations in complement levels.

Tests for immunogenicity had similar results in patients and controls, although zoster IgG concentrations were somewhat lower among patients than controls.

"We don't really know what that means. But patients don't care about their antibody levels -- they care about whether they're going to get shingles," she commented.

Further work will be needed to determine the safety and efficacy of the vaccine for patients younger than 50, who also have significant potential for benefit, and those who are receiving immunosuppressants not okayed by the CDC.

Chakravarty disclosed no relevant relationships with industry.

Primary source: NYU Advanced Rheumatology Seminar
Source reference: Chakravarty E "Vaccines in SLE: when are they appropriate?" NYU Advanced Rheumatology Seminar; March 20-21.

Nancy Walsh has written for various medical publications in the United States and England, including Patient Care, The Practitioner, and the Journal of Respiratory Diseases. She also has contributed numerous essays to several books on history and culture, most recently to The Book of Firsts (Anchor Books, 2010).

Morning Break: Deadbeat Patients, Fish in the Gullet?

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 20, 2014

Business owners who claim that forcing them to provide health insurance that covers contraception violates their religious freedom will get their day in court -- Supreme Court -- next Tuesday when the "Supremes" hear oral arguments on that issue. Kaiser Health News in collaboration with The Daily Beast preview talking points.

An ACA rule could put doctors on the hook for patients who don't pay their insurance premiums. Read MedPage Today's coverage of the AMA's advice to doctors on how to handle such patients.

A New England Journal of Medicine editorial Wednesday called for the Senate to confirm Vivek Murthy, MD as the next surgeon general despite his comments about gun control.

Since laughter is the best medicine, here's your Rx today: Dr. Grumpy relates what not to say to a blind patient.

If anyone has ever told you they felt it in their gut that dark chocolate is good for you, unfortunately, they are sort of right.

WHO says only one-quarter of patients globally with multidrug-resistant TB are diagnosed, but a new initiative is improving the odds.

People are passionate about food, as CNN.com learned from the dozens of responses to a story about the "correct" way to cook quinoa.

A nurse's conviction for encouraging suicides was overturned by the Minnesota Supreme Court Wednesday, ruling unconstitutional parts of a law making it a crime to encourage or advise suicide, Reuters reported.

In case you ever need to remove a live fish from a patient's throat, here's how.

GlaxoSmithKline's MAGE-A3 cancer vaccine disappointed again, this time in a phase III trial for non-small cell lung cancer. Last fall, it fell short as a melanoma treatment.

An op/ed on SGR asks: "Is this anyway to treat America's doctors?" by MedPage Today reader Brian Joondeph, MD.

What's the evidence for evidence-based medicine? asks a blogger at BMJ.

Leana Wen, MD, profiles The Ten Types of ER Patients.

William Heisel looks at what happens after doctors are disciplined by state medical boards.

Who had richer parents, doctors or artists? asks NPR.

The A4 Alzheimer's chemoprevention trial team lays out the plan and rationale in this essay in Science Translational Medicine (sub req'd).

Health reform is literally changing the way medical practices are built.

IBM's Watson will help match glioblastoma patients with optimal treatment as part of a study run by the New York Genome Center.

Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us:   MPT_editorial@everydayhealthinc.com.

MOST READ IN Practice ManagementTOP CME IN Practice Management

Sunday 30 March 2014

Low Back Pain Afflicts Millions Around the World (CME/CE)

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 25, 2014

Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of PennsylvaniaLow back pain causes more global disability than any other condition.
Low back pain arising from ergonomic and occupational exposures is an important cause of disability particularly in the agricultural sector and in developing countries.

Low back pain is on the rise and causes more global disability than any other condition, according to two studies from Australia.

The number of disability-adjusted life years (DALYS) due to low back pain increased from 58.2 million (95% CI 39.9 million-78.1 million) in 1990 to 83 million (95% CI 56.6 million-111.9 million) in 2010, wrote Damian Hoy, PhD, of the University of Queensland, and colleagues in the Annals of the Rheumatic Disease.

"The global point prevalence of [low back pain] was 9.4% (95% CI 9.0-9.8)," they said.

Prevalence was higher in men (mean 10.1%, 95% CI 9.4%-10.7%) compared with women (mean 8.7%, 95% CI 8.2%-9.3%). Both prevalence and burden of disease increased with age, with peak prevalence "at around 80 years of age," the authors wrote.

In a second study appearing in the same issue of the journal, other researchers looked specifically at the global burden of low back pain as a result of exposure to occupational ergonomic risk factors. They estimated that worldwide ergonomic work exposures were responsible for 21.7 million DALYS in 2010.

"Bottom line -- the human cost globally is much higher than previously estimated," James McDeavitt, MD, chair of physical medicine and rehabilitation at Baylor College of Medicine in Houston, told MedPage Today.

High Worldwide Prevalence

The analysis by Hoy's group was part of the Global Burden of Disease (GBD) 2010 study. Out of 291 conditions evaluated, low back pain ranked highest in terms of years lived with disability and sixth in DALYS, the authors said.

They reviewed 117 studies and 780 estimates of burden of disease for low back pain, including data from 85 countries, and 20 of 21 world regions covered by the GBD study. The majority of studies used in the analysis included both men and women, a broad age range, and urban and rural populations.

In the GBD 2010 study, low back pain was de?ned as "pain in the area on the posterior aspect of the body from the lower margin of the 12th ribs to the lower gluteal folds with or without pain referred into one or both lower limbs that lasts for at least 1 day."

Four levels of severity were identified for low back pain, each with their own disability weights. The disability weights were applied to the prevalence values to derive the overall disability of low back pain expressed as years lived with disability.

"The results show that the prevalence and burden of low back pain is very high throughout the world," Hoy's group wrote, adding that because low back pain appears to peak in older age groups, the burden of low back pain ranked higher in regions with longer life expectancies, they said.

In 2010, the age-standardized prevalence was highest in western Europe (mean 15%, 95% CI 14.1-16.0) followed by North Africa/Middle East (mean 14.8%, 95% CI 13.8-15.9).

Prevalence was lowest in the Caribbean (mean 6.5%, 95% CI 5.6-7.4) followed by central Latin America (mean 6.6%, 95% CI 5.8-7.4).

Prevalence did not change signi?cantly from 1990 to 2010, the authors stated.

The study had some limitations. The GBD study of low back pain referred to body function and structure, but did not refer to "broader aspects of life such as participation, well-being, career burden, and economic impact," Hoy's group wrote.

Going forward, "it's important that burden of disease estimates are supplemented with this information to consider the full impact of a condition in a population," they said.

What's more, there was "considerable methodological variation" between studies used in the analysis. The analysis also included the Medical Expenditure Panel Survey (MEPS), the authors said, which might have contained some recall bias, and may not be representative of experiences across the globe.

They called for further research on the duration, severity, and disability over the course of low back pain.

"With expanding and aging populations in many low-income and middle-income countries, the enormous burden from low back pain in these areas will grow significantly over coming decades," they said.

McDeavitt called the current study an improvement over the 1990 GBD and its 2000-2004 follow-up. In the former, the condition was not even reported as an issue because it was not included in the analysis, he said.

In the 2000-2004 update, back pain was reported to rank 105 out of 136 disabling conditions. But "the study was flawed in that it used a definition of spine disease that was highly dependent upon high-tech imaging. Many countries in the study group would not be expected to use imaging to the extent used in developing countries," he said.

The current study attempted to address these methodological challenges, he added.

Ergonomic Exposure

In the second study, Tim Driscoll, PhD, of the University of Sydney, and colleagues, reported that occupational exposure was a substantial contributor to all low back pain, accounting for 28% of all DALYS from low back pain for people, ages 15 and up. The highest relative risk (3.7) was in jobs in the agricultural sector.

They found that 62% of low back pain DALYS were in men, with the largest numbers occurring in those between the ages of 35 and 55. Specifically, of the 21.7 million DALYS in 2010, 13.5 million were in males and 8.3 million in females.

Exposure prevalence was based on occupational distribution, the authors said. Estimates of relative risk were based on a meta-analysis of published literature.

The largest number of DALYS due to work exposure occurred in East Asia and South Asia, "but on a per capita basis the biggest burden was in Oceania," they said.

The absolute burden increased "considerably" from 1990 to 2010, in line with population increases and an aging population, the authors said, "but decreased an average of 14% when calculated on a per capita basis."

The results "provide strong support" for the need to identify, develop, and implement effective interventions that minimize exposure to ergonomic risk factors.

Known risk factors for occupational conditions that lead to low back pain are rapid pace of work, repetitive motion, insufficient recovery time, vibration, heavy lifting, bending, twisting, and sustained non-neutral postures, they explained.

But they cautioned that, when considering interventions, the relationship between various risk factors and low back pain incidence may not be straightforward. Many current interventions are not supported by strong evidence, especially training and administrative measures, they said.

With regard to study limitations, occupation was used as a proxy for exposure to work-related ergonomic factors.

"Ideally, measures of the exposures themselves would be available," the authors said.

In addition, the relative risk for the population attributable fraction was based on a meta-analysis of studies that used "somewhat" different methodologies, and most of the studies used in calculating relative risk were based in developed countries, but were applied to all.

Nonetheless, "what this says is that low back pain is a real problem in this country and others," said Richard Simpson Jr., MD, PhD, a neurosurgeon at Houston Methodist Hospital. "What's needed is a way to get people back to work asap."

Simpson said that getting some people back to work might go beyond preventive measures. Patients who are already incapacitated need to be educated about what resources and strategies are available to them to help them return to the workplace. Some might even require surgery and/or implantable devices if conservative care fails, he said.

The study by Hoy's group was funded by the Bill and Melinda Gates Foundation, the Australian Commonwealth Department of Health and Aging, the Australian National Health and Medical Research Council, and the Aging and Alzheimer's Research Foundation. The authors reported no conflicts of interest.

Driscoll was supported in part by funding from the National Occupational Health and Safety Commission (now Safework Australia). The authors reported no conflicts of interest.

U.S. TB Rate Still Falling

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 24, 2014

The incidence of tuberculosis in the U.S. continues to fall, as it has since 2000, but the disease disproportionately affects people born outside the country, the CDC reported.

The incidence rate was three cases per 100,000 population, which represents a decrease of 4.2% from 2012, the report said.

The proportion of cases occurring in foreign-born people continued to rise, reaching 64.6% in 2013, although the absolute numbers are falling.

That's because the number of cases among native-born Americans is falling more quickly, the agency report said.

However, revised technical instructions for testing immigrants and refugees, started in 2007, appear to be cutting the number of people diagnosed with TB after they arrive in the U.S., the agency said in a separate report.

The analyses, in the March 21 issue of Morbidity and Mortality Weekly Report, appeared just days before World TB Day.

The World Health Organization, in a release to mark the annual March 24 event, noted that nine million people a year fall ill with TB, and three million are missed by health systems.

But fewer are being missed during the immigration and refugee process, the CDC report said, noting that every year about 450,000 people come to the U.S. on an immigrant visa, and between 50,000 and 70,000 arrive as refugees.

In 2007, the agency's technical instructions for TB testing of those people added a requirement for sputum cultures as well as smears.

Some 1,100 cases were detected in 2012, the most recent year with available data, of which 60% were smear-negative but culture-positive and so they would not have been detected using the earlier guidelines.

The increase in diagnoses coincided with a decline in the proportion of newcomers diagnosed with TB after their arrival in the U.S. -- from about 7% to between 1% and 2%, the CDC report said.

One implication of the finding is that referring people for treatment in their home country saved state and local health authorities in the U.S. about $15 million, the agency report argued.

"This program has been one of the largest and most successful interventions in U.S. tuberculosis control during the past decade," said Martin Cetron, MD, director of CDC's Division of Global Migration and Quarantine.

"In addition to creating major savings in healthcare costs," Cetron said in a statement, "the program ensures that immigrants and refugees get prompt care and correct treatment, which is vital to their health, the health of their loved ones, and the U.S. communities where they settle."

In its report on the decline in TB in the U.S., the CDC analyzed provisional surveillance data for 2013, which showed a total of 9,588 new TB cases reported.

The 3,377 TB cases among U.S.-born people -- representing 35.4% of all cases with a known national origin -- was down by 7.6% from the number reported in 2012 and 61% fewer than the number reported in 2000.

The rate among U.S.-born people was 1.2 per 100,000 population -- down 8.4% over 2012 and down 64.7% since 2000.

At the same time, 6,172 cases were reported among foreign-born people -- 64.6% of cases with a known national origin -- which represented a 1.6% decrease since 2012 and a 19% decrease since 2000.

The rate of 15.6 cases per 100,000 population was a 2.1% decrease since 2012 and a 41.1% decrease since 2000.

California, Texas, New York, and Florida combined reported 51.3% of all TB cases reported in 2013, the agency report said.

The agency cautioned that the data underlying the analysis are provisional and that incidence rates are based on population estimates.

North American Correspondent for MedPage Today, is a three-time winner of the Science and Society Journalism Award of the Canadian Science Writers' Association. After working for newspapers in several parts of Canada, he was the science writer for the Toronto Star before becoming a freelancer in 1994. His byline has appeared in New Scientist, Science, the Globe and Mail, United Press International, Toronto Life, Canadian Business, the Toronto Star, Marketing Computers, and many others. He is based in Toronto, and when not transforming dense science into compelling prose he can usually be found sailing.MOST READ IN Infectious Disease

Friday Feedback: Saying You&apos;re Sorry

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 21, 2014

This week, Friday Feedback takes a second look at when doctors say or don't say "sorry." As an alternative model of handling medical errors, apologizing has shown some effectiveness in reducing the number of malpractice lawsuits and is being adopted in various places around the country.

We reached out to a diverse group of physicans and healthcare professionals by email and asked them to respond to the following questions:

How do you admit when there's been an error and how do you say you're sorry?

From your perspective, how effective are new institutional approaches to medical errors?

The participants this week:

Richard C. Boothman, JD, adjunct assistant professor, risk management top executive, clinical affairs, University of Michigan

Neil Brooks, MD, family physician in Vernon, Conn., and former president of the American Academy of Family Physicians

Kevin R. Campbell, MD, cardiologist, UNC Health Care

Shirie Leng, MD, anesthesiologist, and former nurse who blogs at medicine for real and this week wrote, "This is why doctors practice cover your ass medicine"

Russell Libby, MD, founder and president of Virginia Pediatric Group, a primary care pediatric practice with three offices in northern Virginia, and president of the independent practice association HeathConnect IPA

Fred N. Pelzman, MD, an internist at New York Presbyterian-Weill Cornell Medical Center and MedPage Today columnist on patient-centered medical homes

Joan E. Shook, MD, chief safety officer, Texas Children's Hospital and professor of pediatrics, Baylor College of Medicine

Leana S. Wen, MD, MSc, director, patient-centered care research, department of emergency medicine, The George Washington University, blogger and author of When Doctors Don't Listen

Honesty Is the Best Policy

Shirie Leng, MD: "The one time I've informed a patient of a complication I was the cause of, it was a fairly common complication during an epidural procedure; the dura was punctured with the large Tuohy needle. When it happened, I repeated the procedure successfully at a different level and waited until the patient was comfortable with the epidural before I spoke to her about the wet tap."

"I sat down by her bed and explained what had happened, drawing a picture of the epidural space. I then told her what to expect and the steps we could take to ameliorate the headache she would most probably get. I then followed up with her for the next few days and made sure that the OB anesthesia team knew about her every day. I don't actually remember ever saying 'I'm sorry.' I certainly should have."

Richard C. Boothman, JD: Thoroughly understanding what happened and how we can avoid the same outcome for future patients is critical. Disclosures to patients, therefore, are rarely one conversation; instead patients understand it is a process and we work hard to manage their expectations. A poorly-handled disclosure is worse than a delayed, but knowledgeable and sensitive, one. Admissions must be placed in context so patients can process properly the information we are giving them. And we've found that having given patients an opportunity to understand, they are incredibly more understanding and forgiving than anyone ever believed before.

Leana S. Wen, MD, MSc: "We know that patients want transparency, and doctors must be trained to apologize and be open with our patients. The key is to be open, honest, and compassionate, to address the mistake, and to discuss remediation. Defensiveness has no role in this process."

Kevin R. Campbell, MD: "Patients and families respect and appreciate an honest and straightforward approach. It is essential to describe exactly what has happened, why you think it may have occurred, and exactly what you intend to do to rectify the situation and (in some cases ) stabilize and treat the patient."

Relationships Are Key

Fred N. Pelzman, MD: "Having an existing, long-term, strong relationship with patients helps involve them in medical decision-making and plans, and close coordination and follow-up are the best ways to ensure high-quality patient care and avoid errors and bad outcomes."

Leng: "I think prevention of lawsuits happens as soon as the doctor encounters the patient and starts to develop a relationship, way before anything unfortunate occurs. A patient who knows and trusts their doctor is far more likely to understand when a mistake is made. Bedside manner is vastly under-rated. Patients sue because they don't know the doctor, don't trust the doctor, don't like the doctor, or feel that they are not being heard by the doctor.

"Emergency medicine physicians are particularly affected by this, since by the nature of their work they don't have a lot of pre-existing relationships with patients. The same is true of anesthesiologists and radiologists, but the problem really applies to any doctor who encounters a new patient. Maybe that is part of the reason peripartum lawsuits are common."

Russell C. Libby, MD: "Certainly, professional expertise and conduct are usually going to gain the confidence of a patient, but being open to their input, making sure they understand a diagnosis and treatment plan along with its potential for desired as well as undesirable outcomes, and engaging them in making a choice in their care can create a positive relationship."

Joan E. Shook, MD: "At Texas Children's Hospital we believe in full transparency with our patients. We feel that the more transparent an organization is the better outcomes the organization can achieve. But, we know that we are not perfect. When we make a mistake, we are open and transparent with the family, bringing the mistake to their attention as soon as we know about it and discussing what went wrong along the way. We do everything we can to rectify the situation and then keep the family updated each step of the way. We allow the family to ask questions and make sure they have an open forum to be heard. The more engaged you are with a family the more open the family is to working with you toward a solution."

The System Is Broken

Leng: "The current system of American medicine does not promote physician-patient trust. There is plenty of evidence in any number of media outlets that patient trust in physicians is at a very low point. Any condition beyond basic primary care is referred to specialists, who often don't have an established relationship with the patient they are being asked to treat."

Pelzman: "Whatever changes come about, whatever systems we create, be they 'safe harbors,' or tort reform, or medical courts, unless we improve what is leading to these errors doctors will remain loathe to plunge ahead with apologies."

A System for Sorry?

Boothman: "The Michigan Model appeals to universal aspects of human nature -- like the need for respect and patients' deep need to understand what happened to them and why -- that transcend cultural and geographical boundaries. Our approach should be effective literally anywhere. But its efficacy depends first on an institution's willingness to be accountable for mistakes, on its commitment toward improvement, and, overall, on its determination to overcome decades of exaggerated fears about being honest."

Neil Brooks, MD: "Rather than focus on an institutional model, the real focus needs to be on the personal relationship between the primary provider and the patient."

Leng: "Protocols and standards of care don't prevent lawsuits, they only produce cookbook doctors. Empathy and honesty right from the beginning won't prevent lawsuits either, but as some institutions are discovering, they help. Institutional models are all well and good, but bedside manner is a tough thing to teach. A hospital-wide initiative has the positive effect of making people more comfortable with difficult conversations, or at least less afraid of admitting a mistake.

Wen: "Institutional models need to exist to support doctors in mistake disclosure. There also needs to be some degree of protection against malpractice as well; open disclosure can only work if doctors are incentivized to disclose."

Campbell: "Models of early intervention can be effective but must include both hospital administration and physicians together. It is essential that patients see the work that is being done represents the work of an entire 'team.' It must be made clear that all parties are invested in making sure that errors are identified, corrected and prevented in the future -- physicians, nurses, and hospital administrators."

Boothman: "There are several groups studying the Michigan Model in other care environments. Most of those with whom I've worked almost immediately experience the same benefits we've seen. Our experience has graphically taught us this important lesson: that the best healthcare occurs only when we are all in this together."

Shook: "Texas Children's is working to align with the strategies behind the U. of Michigan model. Over the past several years, the hospital has put a big focus on reporting, organizational safety briefings calls, addressing safety issues in real time, measuring safety incidents, putting processes in place to adhere to safety practices, and being transparent in communicating outcomes."

Libby: "Many states have enacted 'I'm Sorry' legislation that allows for empathetic expressions in these difficult situations without implying that they are expressions of guilt. I do believe the concept is integral to the evolving patient-centered medical care approach, representing a new level of mutual responsibility between the patient and their physician.

"I've worked extensively on tort reform in Virginia where we have a unique total cap that we worked out with our trial bar. I have been aware of the 'I'm Sorry' approach to reducing malpractice lawsuits, which comes from a person who lost a sibling (I think) to a medical error. Although there was a reasonable cause, the physician was so reluctant to interact or show empathy. This person did some research, wrote a book, and now runs Sorry Works to reduce malpractice lawsuits."

Barriers

Libby: "The hardest thing to do when something goes wrong is acknowledging it even though you know there may be anger and even threats leveled at you. However, you have been there to help the patient (and their family) and it should not stop when there is an error. I believe it is a form of abandonment when a physician abruptly withdraws and shows no interest or empathy, and it will raise the level of anger and the potential for a lawsuit."

Wen: "It's not easy for doctors to admit that we're wrong, and even harder for us to say that we caused an error."

Pelzman: "We've all made errors, big and small, some of which led to absolutely no harm, some of which likely caused great harm. Apologizing is one of the hardest things we have to do, and there is no better or easier way than to just come right out with it. People are more willing to accept and understand your mistakes if they feel like you were doing your best and looking out for them all along."

Shook: "Even though it can be scary to open up and shine a light on your issues, there is so much that can be learned from doing the exercise especially when it comes to the lives of our patients."

Boothman: "Those who lack the courage to try and the determination to improve have been unable to break from decades of 'deny and defend. They have not seen the benefits we have experienced, not only in medical malpractice numbers, but more importantly in cultural shifts toward transparency that opens to the doors to meaningful peer review, continuous commitment to clinical safety and quality -- and ultimately, a patient-provider relationship of a quality previously unknown in most institutions."

Brooks: "Personal relationships are deteriorating. The reasons are multiple but I'll cite a few:

1. The misuse of the EHR. Too often this has become a barrier between the physician and the patient. Think of your last encounter in which the computer became the focus of the provider's attention. This is not only with the physician, it starts with the front office staff or admitting personnel and extends through virtually every encounter, technicians, nurses, therapists, et al. The patient is too often treated as a biological node that generates data with little concern for their humanity.

2. Failure of physicians to touch the patient. I was recently a patient in an ER in which the physician hardly touched me. Several others have related to me that the same thing happened to them. This lack of contact further denies any real interaction with the patient. Empathy will only be established when it begins at the start of a relationship and not after there is an adverse consequence.

3. Promising too much either explicitly or implicitly. Look at the ads from hospitals and other treatment centers. 'We are the best.' 'No one is as good as we are!' Even doctors use hyperbole in their statements. 'Ten best in the country ... I can do something no one else can.'"

You may also be interested in recent Friday Feedbacks:

How to Stop Overstated Findings

Time to Trash the Medical Home?

Mammograms Useless or Useful?

Friday Feedback is a feature that presents a sampling of opinions solicited by MedPage Today in response to a healthcare issue, clinical controversy, or new finding reported that week. We always welcome new, thoughtful voices. If you'd like to participate in a Friday Feedback issue, reach out to e.chu@medpagetoday.com or @elbertchu.

Elbert Chu, a science and education journalist, has written for The New York Times, Popular Science, Fast Company, and ESPN. Most recently, he produced a multimedia project that investigated abuse of antipsychotics in New York City nursing homes for the Gotham Gazette. In his education mode, Elbert is co-founder of edradar.com, which helps people navigate online education. His documentary photography projects have included Haiti's earthquake, and the aftermath of a school shooting. MOST READ IN Practice ManagementTOP CME IN Practice Management

Ribavirin Works Against Hep E

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
Published: Mar 19, 2014

The antiviral drug ribavirin can clear chronic hepatitis E virus (HEV) in solid-organ transplant recipients, researchers reported.

In a retrospective case series, 3 months of the drug resulted in a sustained virologic response (SVR) in 78% of patients, according to Nassim Kamar, MD, PhD, of the Centre Hospitalier Universitaire Rangueil in Toulouse, France, and colleagues.

Retreatment of six patients who failed the therapy resulted in four achieving an SVR, Kamar and colleagues reported in the March 20 issue of the New England Journal of Medicine.

HEV infection is usually self-limiting, except in patients with a suppressed immune system, where it can evolve to chronic hepatitis and cirrhosis, Kamar and colleagues noted.

There is no established HEV treatment, they added, and simply reducing immunosuppression in transplant patients with HEV only resulted in clearance in about 30%.

To evaluate the effects of ribavirin, they examined case records for 59 solid-organ recipients in 13 French centers who were treated with ribavirin alone between Sept. 10, 2009, and June 27, 2012.

Ribavirin is a general antiviral that inhibits replication of many RNA and DNA viruses. It has long been used to treat hepatitis C, along with pegylated interferon-alfa and now several direct-acting anti-HCV agents.

In the transplant case series, Kamar and colleagues reported, 37 patients got a kidney, 10 got livers, five got hearts, five got a kidney-pancreas transplant, and two got lungs.

Physicians started ribavirin a median of 9 months after HEV was diagnosed, and it was delivered at a median dose of 600 mg daily, equivalent to 8.1 mg/kg of body weight.

Patients got the drug for a median of 3 months (with a range from 1 to 18 months), but 66% got it for 3 months or less, the researchers reported.

One patient who started ribavirin was lost to follow-up after a month of treatment, and another was withdrawn for psychiatric reasons, Kamar and colleagues reported.

Among the remaining 57 patients, 56 had no detectable virus 3 months after the end of their therapy and, of those, 10 had a recurrence of HEV viremia.

Overall, a sustained virologic response -- defined for this study as no detectable viral RNA 6 months after the end of treatment -- was observed in 46 of the 59 patients, or 78%.

At the most recent follow-up -- a median of 25 months after the end of therapy -- the 46 patients were still free of the virus, Kamar and colleagues noted.

Of the 10 patients with relapse, six were retreated with ribavirin and four achieved an SVR.

Analysis found that a higher lymphocyte count when ribavirin therapy was initiated was the only factor associated with a greater likelihood of SVR, the researchers reported.

The main side effect of the drug was anemia, which necessitated a dose reduction in 29% of patients, erythropoietin in 54%, and blood transfusions in 12%, they found.

Kamar and colleagues cautioned that the study was retrospective and had only a small number of patients. In addition, care was clinically driven so that ribavirin dosing, duration, and monitoring varied from patient to patient. Drug levels were not measured.

North American Correspondent for MedPage Today, is a three-time winner of the Science and Society Journalism Award of the Canadian Science Writers' Association. After working for newspapers in several parts of Canada, he was the science writer for the Toronto Star before becoming a freelancer in 1994. His byline has appeared in New Scientist, Science, the Globe and Mail, United Press International, Toronto Life, Canadian Business, the Toronto Star, Marketing Computers, and many others. He is based in Toronto, and when not transforming dense science into compelling prose he can usually be found sailing.MOST READ IN Infectious Disease

Thursday 27 March 2014

Targeted Radiation Might Help Fight Advanced Breast Cancer: Study

News Picture: Targeted Radiation Might Help Fight Advanced Breast Cancer: Study

MONDAY, March 24, 2014 (HealthDay News) -- A minimally invasive treatment that delivers radiation directly to tumors may slow progression of breast cancer that has spread to the liver, a new study suggests.

The treatment is called yttrium 90 (Y-90) radioembolization. Doctors insert a catheter through a tiny cut in the groin and guide it into the artery that supplies the liver. Radiation-emitting micro beads are then sent through the catheter and float out to kill small blood vessels that feed the tumor.

Researchers led by Dr. Robert Lewandowski, an associate professor of radiology at Northwestern University Feinberg School of Medicine in Chicago, looked at the outcomes of 75 patients. The women ranged in age from 26 to 82, and had chemotherapy-resistant breast cancer that had spread to the liver ("metastatic" disease). Their liver tumors were too large or too numerous to be treated with other methods, the authors noted.

Y-90 radioembolization therapy stabilized 98.5 percent of the treated liver tumors, according to the study, which was to be presented Monday in San Diego at the annual meeting of the Society of Interventional Radiology.

In addition, 24 of the women experienced a more than 30 percent shrinkage in tumor size after treatment, which caused few side effects.

"Although this is not a cure, Y-90 radioembolization can shrink liver tumors, relieve painful symptoms, improve the quality of life and potentially extend survival," Lewandowski said in a society news release.

"While patient selection is important, the therapy is not limited by tumor size, shape, location or number, and it can ease the severity of disease in patients who cannot be treated effectively with other approaches," he added.

Two breast cancer experts were cautiously optimistic about the findings.

According to Dr. Neelima Denduluri, "while these results appear promising, this is a very small retrospective study," meaning that it fell short of the "gold standard" type of prospective trial that tracks patients going forward over time. "Randomized controlled prospective studies addressing this issue are necessary before radioembolization can be incorporated routinely," she believes.

For now, "in women that cannot receive systemic therapy due to toxicities [side effects], are not eligible for clinical trials that utilize new agents, or have exhausted conventional chemotherapy options, radioembolization may be a choice," said Denduluri, a medical oncologist with Virginia Cancer Specialists in Arlington, Va., a US Oncology Network affiliate.

Dr. Stephanie Bernik is chief of surgical oncology at Lenox Hill Hospital in New York City. She said that while this type of therapy has been used to fight liver tumors, "the ability to use this therapy in treatment of metastatic breast cancer to the liver offers some hope to patients with the disease."

Bernik stressed that, right now, the treatment can only extend survival for women with advanced breast cancer, it is not a cure. However, "as the technique is modified and perfected, it is hoped the [treatment] can help achieve remission in women with advanced disease."

Each year in the United States, about 117,000 patients are diagnosed with breast cancer that has spread to the liver. Chemotherapy is the standard treatment in such cases, but is not effective in, or suitable for, all patients.

Experts note that studies presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

-- Robert Preidt MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCES: Neelima Denduluri, M.D., medical oncologist, Virginia Cancer Specialists, Arlington, Va., a US Oncology Network affiliate; Stephanie Bernik, M.D., chief of surgical oncology, Lenox Hill Hospital, New York City; Society of Interventional Radiology, news release, March 24, 2014



View the original article here

Tiny Wireless Pacemaker Shows Early Promise

News Picture: Tiny Wireless Pacemaker Shows Early PromiseBy Dennis Thompson
HealthDay Reporter

MONDAY, March 24, 2014 (HealthDay News) -- A new wireless pacemaker appears safe and feasible for use, potentially advancing the technology that cardiologists use to maintain heart rhythm in patients, according to results from a new clinical trial.

Doctors successfully implanted the device in 32 out of 33 patients. Of these, two people who received the pacemaker developed side effects -- a complication-free rate of 94 percent. Complications for the patient with unsuccessful implantation, however, proved to be severe.

After three months, the new pacemakers continued to function well, the researchers reported in the April 8 issue of the journal Circulation. They expect to report longer-term outcomes later this year.

The concept of a self-contained wireless pacemaker has been around more than 40 years, and this first successful use of such a device to treat humans is considered a step forward for cardiology.

"This is an advance that will have a huge impact on the field," said Dr. Bradley Knight, a cardiologist at the Northwestern University Feinberg School of Medicine and a spokesman for the American Heart Association. "This opens up a whole bunch of new potential opportunities for pacing a patient's heart."

Today's pacemakers maintain the heart's rhythm by sending electrical signals through wires that run from the device into the heart through a person's veins, said the study's lead author, Dr. Vivek Reddy, director of the cardiac arrhythmia service at Mount Sinai Hospital in New York City.

"These leads are the weak link for the whole system," Reddy said of the wires. The leads tend to break over time, and when they do doctors must extract and replace them.

Unfortunately, the wires sometimes grow into the wall of the vein, and laser surgery could be required to cut them free.

This new wireless pacemaker contains its own pulse generator, and is affixed directly inside the right ventricle of the heart through a catheter run up a vein from a patient's leg or groin, Reddy said. The nonsurgical procedure is faster and easier than the surgery currently required to implant a pacemaker, the researchers said.

The unit itself is smaller than a triple-A battery -- 6 millimeters in diameter and about 42 millimeters long. "The total amount of space it displaces is about 1 cc of fluid, so it's very, very small," Reddy said.

The wireless pacemaker is expected to operate for eight to 14 years before it runs out of juice, Reddy said.

The pacemaker is manufactured by Nanostim Inc., of Sunnyvale, Calif. The study was funded by Nanostim, which, according to the study, employs two of the researchers and has provided several more with grant support. Reddy also has stock options in the company.

The clinical trial for the device involved 33 patients at two hospitals in Prague and one in Amsterdam. The average age of the patients was 77, and two-thirds were men.

One patient experienced complications during the implant procedure, and this case highlights one of the potential problems with the new pacemaker, Reddy and Knight said.

Since the device must be placed inside the heart, there is a risk that the heart muscle can be torn during the procedure. That's what happened to the 33rd patient, who underwent emergency surgery to repair the tear but later died after suffering a stroke.

Two patients who successfully received the implant later developed complications.

In one patient, the pacemaker drifted into another heart chamber through a hole in the person's heart wall left by a birth defect. Doctors discovered the problem, removed the device in about six minutes and replaced it with another wireless pacemaker, according to the study.

The second patient with complications experienced fainting and rapid heart beat, and doctors ended up replacing the pacemaker with an implantable cardioverter-defibrillator.

Also, the pacemaker initially would be of limited use in the United States because it can only provide pacing to one chamber of the heart. Between 75 percent and 80 percent of patients in the United States need pacemakers that help control the rhythm of both the upper and lower chambers of their heart, Reddy said.

This wireless pacemaker would at first be useful in treating people who have atrial fibrillation -- an irregular heartbeat -- since they need pacing only in their right ventricle, Knight said. It also could help people with less severe heart problems who need only intermittent pacing.

Knight said he believes problems related to heart tears and single-chamber pacing will be resolved as newer, smaller models of wireless pacemaker become available.

"This is just the beginning," he said. "These things will get smaller and be able to be placed in multiple locations in the heart."

For example, dual-chamber pacemaking could be achieved using a pair of the wireless devices -- one in the upper atrial chamber and another in the lower ventricular chamber -- if communication is established between them to sync their pulses.

Clinical trials for the device already have begun in the United States, Reddy said. The first American received a wireless pacemaker about a month ago at Mount Sinai Hospital.

Researchers hope the device can receive approval from the U.S. Food and Drug Administration by 2016. The wireless pacemaker currently is available to patients outside the United States, Reddy said.

The medical device firm Medtronic has developed a competing wireless pacemaker, Reddy said, and clinical trials for that device started in late 2013.

Because of the competition, Reddy expects that the new pacemakers will be more expensive than current devices but not exorbitantly so.

"I'm sure they'll charge a premium in the beginning, but if there's any competition they can't charge too much more," he said.

MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCES: Vivek Reddy, M.D., director, cardiac arrhythmia service, Mount Sinai Hospital, New York City; Bradley Knight, M.D., cardiologist, Northwestern University Feinberg School of Medicine, Chicago, and spokesman, American Heart Association; April 8, 2014, Circulation



View the original article here

Blindness Rates Dropping Worldwide, Study Finds


View the original article here

Violent Video Games Tied to Combative Thinking in Study

News Picture: Violent Video Games Tied to Combative Thinking in StudyBy Alan Mozes
HealthDay Reporter

MONDAY, March 24, 2014 (HealthDay News) -- Frequent exposure to violent video games increases the likelihood that children and teens will engage in aggressive behavior themselves, new research indicates.

The study of more than 3,000 children found that habitually playing games such as "Call of Duty" and "God of War" might alter their view of their real-world environment and peers, the researchers said.

"[Violent gaming] basically changes a child's or adolescent's personality in some sense, so that they start to see their world in a more aggressive way," said study co-author Craig Anderson, director of the Center for the Study of Violence at Iowa State University.

"They start to expect people to behave more aggressively toward them, and they tend to see aggressive solutions as being more appropriate for solving problems," Anderson said.

More than 90 percent of American kids play video games, many of which portray violence in a fun framework free of negative consequences, the researchers said. Because of these large numbers, research such as this has significant implications, they said.

Still, parents shouldn't panic, Anderson said.

"Playing a violent video game isn't going to take a healthy kid who has few other risk factors and turn him into a school shooter," he said. "But it is a risk factor that does drive the odds for aggression up significantly."

Anderson said there are many other known risk factors for aggression, such as growing up with parents who are visibly aggressive or living in a violent neighborhood.

The children enrolled in the study, which was published online March 24 in the journal JAMA Pediatrics, came from six primary and six secondary schools in Singapore. All were between 8 and 17 years old, and nearly three-quarters were boys.

For three years, the students were surveyed annually about the time they spent playing video games and about the nature of their favorite games.

In addition, the children discussed their feelings of empathy and aggression, and were asked about any past aggressive behaviors. For example, children were asked if they felt it was OK to respond to certain provocative situations by hitting someone, whether they ever thought about hurting a peer and whether seeing someone else who was upset bothered them.

By stacking violent video game habits up against aggressive thought patterns and behavior, the investigators determined that during the three-year study period kids with a lot of exposure to violent video games were more likely to engage in aggressive behavior.

This link seemed to result from a lasting increase in aggressive thinking, the researchers said. That included a rise in aggressive fantasies, and a growing tendency to attribute hostile motives to others.

The shifts in thinking associated with heavy use of violent games occurred for both girls and boys, even when parents monitored their child's gaming habits. The changes were also found to be independent of a child's initial aggressiveness, the study found.

The researchers also said having feelings of empathy didn't seem to dampen the link between violent gaming and aggression, and the link was seen more or less across all age groups.

The authors said more research is needed to better understand the effects of playing video games that glorify brutality. "[But] at least one major reason aggressive behavior went up in children is because violent video games seemed to increase a child's violent thought patterns," Anderson said.

Richard Gallagher, director of the Parenting Institute at the New York University Child Study Center, said he wasn't surprised by the findings.

"Research data with persons of all ages has consistently indicated that playing violent video games does change attitudes and does possibly alter behavioral tendencies," he said. "And it's looking like it shifts kids to what's considered to be a kind of disturbed and biased thinking."

This is important for people to know in terms of public policy and parenting, Gallagher said.

"These kinds of games are not benign," he said. "They might not cause all kids to get involved with negative and aggressive behavior, but they do push them more in that direction."

MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCES: Craig Anderson, Ph.D., distinguished professor, psychology, and director, Center for the Study of Violence, Iowa State University, Ames, Iowa, and past president, International Society for Research on Aggression; Richard Gallagher, Ph.D., director, Parenting Institute, and associate professor, New York University Child Study Center, New York City; March 24, 2014, JAMA Pediatrics, online



View the original article here

Wednesday 26 March 2014

New Therapy May Shrink Enlarged Prostate With Fewer Side Effects: Study

News Picture: New Therapy May Shrink Enlarged Prostate With Fewer Side Effects: Study

MONDAY, March 24, 2014 (HealthDay News) -- A new noninvasive procedure may bring long-term relief from symptoms caused by an enlarged prostate, a new study suggests.

As men age, the prostate gland grows larger and may begin to press on the urethra. Enlarged prostate affects more than half of men by age 60 and causes symptoms such as frequent urination, weak urine stream and a persistent feeling of having to urinate.

Surgery is the standard treatment for the condition, but can cause complications such as sexual dysfunction and impotence, experts note.

The new treatment is called prostate artery embolization. "Prostate artery embolization is a promising therapy that has been performed outside the United States to improve men's symptoms," explained Dr. Man Hon, chief of interventional radiology at Winthrop University Hospital in Mineola, N.Y.

"This procedure works by closing the blood supply to the prostate," said Hon, who was not involved in the new study. "As a result, the prostate shrinks in size, causes less blockage, and the symptoms improve."

The study was conducted in Portugal and included nearly 500 men, aged 45 to 89, with enlarged prostate -- formally called benign prostatic hyperplasia -- who underwent prostate artery embolization.

Improvements in symptoms were reported by 87 percent of men three months after the procedure, 80 percent after 18 months, and 72 percent after three years. The procedure did not cause sexual dysfunction or impotence, according to the findings, which were slated for presentation on Monday at the annual meeting of the Society of Interventional Radiology (SIR), in San Diego.

"The results of prostate artery embolization (PAE) are similar to surgery but with fewer complications," study author Dr. Martins Pisco, director of radiology at Saint Louis Hospital in Lisbon, said in a meeting news release. "Patients are discharged three to six hours after the treatment with most of the individuals we've treated noting almost immediate symptom relief."

"I believe PAE could eventually become standard treatment for enlarged prostate," he added.

However, Dr. James Spies, president elect of SIR, stressed that further studies are needed before the procedure could become widely available. Also, studies presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

Another expert agreed that more study is needed. Dr. Manish Vira is director of the Fellowship Program in Urologic Oncology at The Arthur Smith Insitute for Urology in New Hyde Park, NY. He pointed out that the Portuguese study was not designed to compare the success rate of embolization to that of other treatments.

However, Vira added that "the results are especially significant given the very low complication rate and no incontinence. If these results are replicated in the ongoing U.S. trials, then prostate artery embolization will become an attractive treatment option" for men with enlarged prostate who have not responded well to other treatments.

-- Robert Preidt MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCES: Manish A. Vira, M.D, director, Fellowship Program in Urologic Oncology, The Arthur Smith Institute for Urology, New Hyde Park, NY; Man Hon, M.D, chief, interventional radiology, Winthrop University Hospital, Mineola, NY; Society of Interventional Radiology, annual meeting news release, March 24, 2014



View the original article here

Anti-Seizure Drug May Guard Against Some Cancers

News Picture: Anti-Seizure Drug May Guard Against Some Cancers

MONDAY, March 24, 2014 (HealthDay News) -- A drug used to treat seizures may reduce the risk of head and neck cancers, a new study suggests.

Valproic acid (Depakote) is prescribed to prevent seizures and also to control mood, but it is also being investigated for cancer prevention because it inhibits genetic changes that can lead to cancer.

The new study included nearly 440,000 U.S. veterans, including about 27,000 who were taking valproic acid for bipolar disorder, post-traumatic stress disorder (PTSD), migraines and seizures. Overall, veterans who took the drug for at least one year were 34 percent less likely to develop head and neck cancers than those who didn't take the drug, the investigators found.

The risk appeared to be even lower in those who took it in higher doses or for longer periods of time, according to the study published online March 24 in the journal Cancer.

Veterans who took valproic acid did not have a reduced risk for lung, bladder, colon or prostate cancers, said team leader Dr. Johann Christoph Brandes, of the Atlanta Veterans Affairs Medical Center and Emory University in Atlanta, and colleagues.

"A 34 percent risk reduction for the development of head and neck cancer with [valproic acid] use could result in the prevention of up to approximately 16,000 new cases and 3,000 to 4,000 annual deaths in the U.S. alone," Brandes said in a journal news release.

"Head and neck cancer is an important global health crisis, and low cost and low toxicity prevention strategies like [valproic acid] use have a high potential impact on pain, suffering, costs, and [death] associated with this disease," he added.

Although the study found an association between valproic acid use and reduced risk of certain cancers, it did not prove cause-and-effect.

-- Robert Preidt MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCE: Cancer, news release, March 24, 2014



View the original article here

Spanking Triggers Vicious Cycle, Study Finds


View the original article here

New Guidelines Might Limit Need for Lymph Node Removal for Breast Cancer

News Picture: New Guidelines Might Limit Need for Lymph Node Removal for Breast Cancer

MONDAY, March 24, 2014 (HealthDay News) -- Biopsies of so-called "sentinel" lymph nodes under the arms should become more widespread among breast cancer patients, according to updated guidelines from the American Society of Clinical Oncology (ASCO).

The group, which represents cancer specialists, said the new recommendations should also restrict the number of women who will require further removal of multiple nodes after biopsy, cutting down on painful side effects.

In sentinel lymph node biopsy, a few lymph nodes are removed and checked for signs of cancer -- hence the name "sentinel." Usually, if these lymph nodes have no cancer, it means the remaining, unchecked lymph nodes should also be cancer-free.

The new ASCO recommendations expand eligibility for sentinel node biopsy and will reduce the number of patients who undergo a more invasive procedure called axillary -- underarm -- lymph node dissection, which carries a higher risk of complications, the group said.

In axillary lymph node dissection, most lymph nodes under the arm on the same side as the breast tumor are removed and examined for cancer. This procedure can cause long-term side effects such as pain and numbness in the arm and swelling due to a build-up of lymph fluid.

The new guidelines state that for women whose sentinel lymph nodes show no signs of cancer, removal of more underarm lymph nodes is not recommended.

The guidelines also addressed the case of women who undergo lumpectomy instead of full mastectomy and are also scheduled for whole-breast radiation therapy to help "mop up" residual cancer. If these patients have signs of cancer in only one or two sentinel lymph nodes upon biopsy, they too may opt to avoid further node removal, the ASCO experts said.

Women who have undergone mastectomy but show signs of cancer's spread in sentinel lymph nodes should be offered further node removal, the guidelines reaffirmed.

The ASCO also said women who are diagnosed with certain breast cancers while pregnant can skip sentinel node biopsy.

The ASCO issued initial guidelines on sentinel node biopsy in 2005. The new guidelines, published March 24 in the Journal of Clinical Oncology, are based on the findings of a panel of experts who reviewed studies published between 2004 and 2013.

"The updated guideline incorporates new evidence from more recent studies -- nine randomized controlled trials and 13 cohort studies since 2005," panel co-chairman Dr. Armando Giuliano said in an ASCO news release.

"Based on these studies, we're saying more patients can safely get sentinel node biopsy without axillary lymph node [removal]," he said. "These guidelines help determine for whom sentinel node biopsy is appropriate."

Panel co-chairman Dr. Gary Lyman said, "We strongly encourage patients to talk with their surgeon and other members of their multidisciplinary team to understand their options and make sure everybody is on the same page."

"The most critical determinant of breast cancer prognosis is still the presence and extent of lymph node involvement," he said. "Therefore, the lymph nodes need to be evaluated so we can understand the extent of the disease."

Two breast cancer specialists welcomed the new guidelines.

"Over the past few years, there has been a movement to limit the amount of axillary [lymph node] surgery in patients undergoing breast conservation," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.

Bernik said the new guidelines are important because some doctors have been reluctant to move away from further underarm node removal when a patient has even one affected sentinel node. "This update will give surgeons the confidence to tell patients that a sentinel lymph node biopsy may be enough, even if there is evidence of spread, in patients undergoing [lumpectomy]," Bernik said.

"However, it is still important for surgeons to discuss the pros and cons with a patient, as not all [real-world] patients fit the study criteria," she said. "Furthermore, it needs to be stressed that the more limited surgery does not apply to women undergoing mastectomies."

Dr. Debra Patt is the medical director of an expert panel that assesses cancer care guidelines for the US Oncology Network. She said she was "thrilled" at the new ASCO guidelines because they seem to echo the results of recent studies.

"In 2010, a study presented at the ASCO annual meeting showed that women undergoing breast-conservation surgery with clinically node-negative small breast cancers could safely avoid removing all the lymph nodes from under the arm in most cases," Patt said. "There has been greater variance in treatment patterns in my community practice, and I believe these updated guidelines will direct practitioners to evidence-based patient care."

-- Robert Preidt MedicalNews
Copyright © 2014 HealthDay. All rights reserved. SOURCES: Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Debra Patt, M.D., medical director, Pathways Task Force and Healthcare Informatics, US Oncology Network; American Society of Clinical Oncology, news release, March 24, 2014



View the original article here

Friday 21 March 2014

Genetics Home Reference: fragile XE syndrome

Fragile XE syndrome is a genetic disorder that impairs thinking ability and cognitive functioning. Most affected individuals have mild intellectual disability. In some people with this condition, cognitive function is described as borderline, which means that it is below average but not low enough to be classified as an intellectual disability. Females are rarely diagnosed with fragile XE syndrome, likely because the signs and symptoms are so mild that the individuals function normally.

Learning disabilities are the most common sign of impaired cognitive function in people with fragile XE syndrome. The learning disabilities are likely a result of communication and behavioral problems, including delayed speech, poor writing skills, hyperactivity, and a short attention span. Some affected individuals display autistic behaviors, such as hand flapping, repetitive behaviors, and intense interest in a particular subject. Unlike some other forms of intellectual disability, cognitive functioning remains steady and does not decline with age in fragile XE syndrome.

Fragile XE syndrome is estimated to affect 1 in 25,000 to 100,000 newborn males. Only a small number of affected females have been described in the medical literature. Because mildly affected individuals may never be diagnosed, it is thought that the condition may be more common than reported.

Fragile XE syndrome is caused by mutations in the AFF2 gene. This gene provides instructions for making a protein whose function is not well understood. Some studies show that the AFF2 protein can attach (bind) to DNA and help control the activity of other genes. Other studies suggest that the AFF2 protein is involved in the process by which the blueprint for making proteins is cut and rearranged to produce different versions of the protein (alternative splicing). Researchers are working to determine which genes and proteins are affected by AFF2.

Nearly all cases of fragile XE syndrome occur when a region of the AFF2 gene, known as the CCG trinucleotide repeat, is abnormally expanded. Normally, this segment of three DNA building blocks (nucleotides) is repeated approximately 4 to 40 times. However, in people with fragile XE syndrome, the CCG segment is repeated more than 200 times, which makes this region of the gene unstable. (When expanded, this region is known as the FRAXE fragile site.) As a result, the AFF2 gene is turned off (silenced), and no AFF2 protein is produced. It is unclear how a shortage of this protein leads to intellectual disability in people with fragile XE syndrome.

People with 50 to 200 CCG repeats are said to have an AFF2 gene premutation. Current research suggests that people with a premutation do not have associated cognitive problems.

Read more about the AFF2 gene.

Fragile XE syndrome is inherited in an X-linked dominant pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, which is one of the two sex chromosomes. In females (who have two X chromosomes), a mutation in one of the two copies of the gene in each cell is sufficient to cause the disorder. In males (who have only one X chromosome), a mutation in the only copy of the gene in each cell causes the disorder. In most cases, males experience more severe symptoms of the disorder than females.

In parents with the AFF2 gene premutation, the number of CCG repeats can expand to more than 200 in cells that develop into eggs or sperm. This means that parents with the premutation have an increased risk of having a child with fragile XE syndrome. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons; sons receive a Y chromosome from their father, which does not include the AFF2 gene.

These resources address the diagnosis or management of fragile XE syndrome and may include treatment providers.

You might also find information on the diagnosis or management of fragile XE syndrome in Educational resources and Patient support.

General information about the diagnosis and management of genetic conditions is available in the Handbook. Read more about genetic testing, particularly the difference between clinical tests and research tests.

To locate a healthcare provider, see How can I find a genetics professional in my area? in the Handbook.

You may find the following resources about fragile XE syndrome helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

FRAXE intellectual deficitFRAXE intellectual disabilityFRAXE mental retardation syndromeFRAXE syndromemental retardation, X-linked, associated with fragile site FRAXEmental retardation, X-linked, FRAXE type

For more information about naming genetic conditions, see the Genetics Home Reference Condition Naming Guidelines and How are genetic conditions and genes named? in the Handbook.

The Handbook provides basic information about genetics in clear language.

These links provide additional genetics resources that may be useful.

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? in the Handbook.


View the original article here

Genetics Home Reference: hereditary diffuse gastric cancer

Hereditary diffuse gastric cancer (HDGC) is an inherited disorder that greatly increases the chance of developing a form of stomach (gastric) cancer. In this form, known as diffuse gastric cancer, there is no solid tumor. Instead cancerous (malignant) cells multiply underneath the stomach lining, making the lining thick and rigid. The invasive nature of this type of cancer makes it highly likely that these cancer cells will spread (metastasize) to other tissues, such as the liver or nearby bones.

Symptoms of diffuse gastric cancer occur late in the disease and can include stomach pain, nausea, vomiting, difficulty swallowing (dysphagia), decreased appetite, and weight loss. If the cancer metastasizes to other tissues, it may lead to an enlarged liver, yellowing of the eyes and skin (jaundice), an abnormal buildup of fluid in the abdominal cavity (ascites), firm lumps under the skin, or broken bones.

In HDGC, gastric cancer usually occurs in a person's late thirties or early forties, although it can develop anytime during adulthood. If diffuse gastric cancer is detected early, the survival rate is high; however, because this type of cancer is hidden underneath the stomach lining, it is usually not diagnosed until the cancer has become widely invasive. At that stage of the disease, the survival rate is approximately 20 percent.

Some people with HDGC have an increased risk of developing other types of cancer, such as a form of breast cancer in women that begins in the milk-producing glands (lobular breast cancer); prostate cancer; and cancers of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer. Most people with HDGC have family members who have had one of the types of cancer associated with HDGC. In some families, all the affected members have diffuse gastric cancer. In other families, some affected members have diffuse gastric cancer and others have another associated form of cancer, such as lobular breast cancer. Frequently, HDGC-related cancers develop in individuals before the age of 50.

Gastric cancer is the fourth most common form of cancer worldwide, affecting 900,000 people per year. HDGC probably accounts for less than 1 percent of these cases.

It is likely that 30 to 40 percent of individuals with HDGC have a mutation in the CDH1 gene. The CDH1 gene provides instructions for making a protein called epithelial cadherin or E-cadherin. This protein is found within the membrane that surrounds epithelial cells, which are the cells that line the surfaces and cavities of the body. E-cadherin helps neighboring cells stick to one another (cell adhesion) to form organized tissues. E-cadherin has many other functions including acting as a tumor suppressor protein, which means it prevents cells from growing and dividing too rapidly or in an uncontrolled way.

People with HDGC caused by CDH1 gene mutations are born with one mutated copy of the gene in each cell. These mutations cause the production of an abnormally short, nonfunctional version of E-cadherin or alter the protein's structure. For diffuse gastric cancer to develop, a second mutation involving the other copy of the CDH1 gene must occur in the cells of the stomach lining during a person's lifetime. People who are born with one mutated copy of the CDH1 gene have a 70 percent chance of acquiring a second mutation in the other copy of the gene and developing gastric cancer in their lifetimes.

When both copies of the CDH1 gene are mutated in a particular cell, that cell cannot produce any functional E-cadherin. The loss of this protein prevents it from acting as a tumor suppressor, contributing to the uncontrollable growth and division of cells. A lack of E-cadherin also impairs cell adhesion, increasing the likelihood that cancer cells will not come together to form a tumor but will invade the stomach wall and metastasize as small clusters of cancer cells into nearby tissues.

These CDH1 gene mutations also lead to a 60 percent chance of lobular breast cancer, a slightly increased risk of prostate cancer in men, and a slightly increased risk of colorectal cancer. It is unclear why CDH1 gene mutations primarily occur in the stomach lining and these other tissues.

About 60 to 70 percent of individuals with HDGC do not have an identified mutation in the CDH1 gene. The cancer-causing mechanism in these individuals is unknown.

Read more about the CDH1 gene.

HDGC is inherited in an autosomal dominant pattern, which means one copy of the altered CDH1 gene in each cell is sufficient to increase the risk of developing cancer.

In most cases, an affected person has one parent with the condition.

These resources address the diagnosis or management of hereditary diffuse gastric cancer and may include treatment providers.

You might also find information on the diagnosis or management of hereditary diffuse gastric cancer in Educational resources and Patient support.

General information about the diagnosis and management of genetic conditions is available in the Handbook. Read more about genetic testing, particularly the difference between clinical tests and research tests.

To locate a healthcare provider, see How can I find a genetics professional in my area? in the Handbook.

You may find the following resources about hereditary diffuse gastric cancer helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

E-cadherin-associated hereditary gastric cancerfamilial diffuse gastric cancerFDGCHDGChereditary diffuse gastric adenocarcinoma

For more information about naming genetic conditions, see the Genetics Home Reference Condition Naming Guidelines and How are genetic conditions and genes named? in the Handbook.

The Handbook provides basic information about genetics in clear language.

These links provide additional genetics resources that may be useful.

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? in the Handbook.


View the original article here

Genetics Home Reference: megalencephaly-capillary malformation syndrome

Megalencephaly-capillary malformation syndrome (MCAP) is a disorder characterized by overgrowth of several tissues in the body. Its primary features are a large brain (megalencephaly) and abnormalities of small blood vessels in the skin called capillaries (capillary malformations).

In individuals with MCAP, megalencephaly leads to an unusually large head size (macrocephaly), which is typically evident at birth. After birth, the brain and head continue to grow at a fast rate for the first few years of life; then, the growth slows to a normal rate, although the head remains larger than average. Additional brain abnormalities are common in people with MCAP; these can include excess fluid within the brain (hydrocephalus) and abnormalities in the brain's structure, such as those known as Chiari malformation and polymicrogyria. Abnormal brain development leads to intellectual disability in most affected individuals and can also cause seizures or weak muscle tone (hypotonia). In particular, polymicrogyria is associated with speech delays and difficulty chewing and swallowing.

The capillary malformations characteristic of MCAP are composed of enlarged capillaries that increase blood flow near the surface of the skin. These malformations usually look like pink or red spots on the skin. In most affected individuals, capillary malformations occur on the face, particularly the nose, the upper lip, and the area between the nose and upper lip (the philtrum). In other people with MCAP, the malformations appear as patches spread over the body or as a reddish net-like pattern on the skin (cutis marmorata).

In some people with MCAP, excessive growth affects not only the brain but other individual parts of the body, which is known as segmental overgrowth. This can lead to one arm or leg that is bigger or longer than the other or a few oversized fingers or toes. Some affected individuals have fusion of the skin between two or more fingers or toes (cutaneous syndactyly).

Additional features of MCAP can include flexible joints and skin that stretches easily. Some affected individuals are said to have doughy skin because the tissue under the skin is unusually thick and soft.

The gene involved in MCAP is also associated with several types of cancer. Although a small number of individuals with MCAP have developed tumors (in particular, a childhood form of kidney cancer known as Wilms tumor and noncancerous tumors in the nervous system known as meningiomas), people with MCAP do not appear to have a greater risk of developing cancer than the general population.

These resources address the diagnosis or management of megalencephaly-capillary malformation syndrome and may include treatment providers.

You might also find information on the diagnosis or management of megalencephaly-capillary malformation syndrome in Educational resources and Patient support.

General information about the diagnosis and management of genetic conditions is available in the Handbook. Read more about genetic testing, particularly the difference between clinical tests and research tests.

To locate a healthcare provider, see How can I find a genetics professional in my area? in the Handbook.

You may find the following resources about megalencephaly-capillary malformation syndrome helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

The Handbook provides basic information about genetics in clear language.

These links provide additional genetics resources that may be useful.

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? in the Handbook.


View the original article here